Using the inhibitor olmasartan, Masamune et al. (2013) report a significant decrease in primary tumor growth accompanied by decreased α-SMA staining and ECM production in mice injected with a mixture of PSCs and cancer cells, but not in mice injected with cancer cells alone. This evidence concerns the gene ACTA1 and cancer.